FERRARA , Micol

Last name: FERRARA

First name: Micol

2023 (v1)

Publication

Metadata-only

Residual phenotypic susceptibility to doravirine in multidrug resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry

Saladini, Francesco Giammarino, Federica Maggiolo, Franco

Background: Doravirine shows a rather distinct resistance profile within the NNRTI class. This study aimed to evaluate the phenotypic susceptibility to doravirine, rilpivirine and etravirine in a panel of multidrug-resistant (MDR) HIV-1 isolates collected from people living with HIV (PLWH) enrolled in the PRESTIGIO Registry. Methods:...

Uploaded on: February 7, 2024
2024 (v1)

Publication

Metadata-only

Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors

Clemente, Tommaso Galli, Laura Lolatto, Riccardo

Purpose: The PRESTIGIO Registry was established in 2017 to collect clinical, virological and immunological monitoring data from people living with HIV (PLWH) with documented four-class drug resistance (4DR). Key research purposes include the evaluation of residual susceptibility to specific antiretrovirals and the validation of treatment and...

Uploaded on: July 3, 2024
2020 (v1)

Publication

Metadata-only

Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study

Muscatello, Antonio Nozza, Silvia Fabbiani, Massimiliano

Viral load peak and immune activation occur shortly after exposure during acute or early HIV infection (AEHI). We aimed to define the benefit of early start of antiretroviral treatment (ART) during AEHI in terms of immunological recovery, virological suppression, and treatment discontinuation.

Uploaded on: April 14, 2023

FERRARA , Micol

Recent uploads